-+ 0.00%
-+ 0.00%
-+ 0.00%

SciBase publishes 2025 annual report

PUBT·04/27/2026 14:13:44
Listen to the news
SciBase publishes 2025 annual report
  • SciBase published its 2025 annual report, highlighting accelerated commercial momentum driven by US expansion.
  • US skin cancer sales rose 148%, supported by a broadened customer base and higher electrode utilization.
  • Castle Biosciences collaboration launched in June 2025 to develop atopic dermatitis flare-prediction testing using Nevisense, with first study planned for H1 2026.
  • Partnership deepened with a SEK 20 million loan from Castle to speed production investments, alongside an initial clinical-study order worth about SEK 8 million with deliveries starting in Q4 2025.
  • Product roadmap advanced with launch of next-generation Nevisense V platform, while European expansion added initial system sales to Italy.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. SciBase Holding AB published the original content used to generate this news brief on April 27, 2026, and is solely responsible for the information contained therein.